Literature DB >> 12873170

Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus.

Jacqueline M Seabrook1, Roger A Hubbard.   

Abstract

Laboratories contemplating either the addition of new molecular tests or modifying methods approved by the Food and Drug Administration for human papillomavirus testing should be aware of a variety of procedural, performance, and regulatory issues surrounding such activity. Diagnostic medical laboratory testing in the United States is regulated by the Centers for Medicare and Medicaid Services, an agency formerly known as the Health Care Finance Administration. The regulatory vehicle of the Centers for Medicare and Medicaid Services is manifested in the Clinical Laboratory Improvement Amendments (CLIA). The CLIA program has put into place specific regulations for laboratory quality control, which includes specific recommendations for method validation. Regulations that must be followed regarding personnel, quality control, quality assurance, method validation, and proficiency testing depend on the complexity category of the individual test. All molecular diagnostic tests, including those for human papillomavirus, are considered high complexity. The Centers for Medicare and Medicaid Services retains the authority to allow private, national accreditation organizations to "deem" that a laboratory is compliant with CLIA '88 requirements. Accreditation organizations, such as the Joint Commission for Accreditation of Hospitals, the Commission on Office Laboratory Accreditation, and the College of American Pathologists (CAP), as well as several state medical laboratory-accrediting agencies, possess the authority to deem laboratories as "CLIA-approved." The CAP, through its Laboratory Accreditation Program, has promoted standards for laboratory performance and method validation. In general, guidelines set forth in the CAP Laboratory Accreditation Program checklists specify that all clinical laboratory testing must essentially meet those requirements defined for high-complexity testing under CLIA '88, including test validation standards, reportable/reference ranges, performance criteria, and proficiency testing.

Entities:  

Mesh:

Year:  2003        PMID: 12873170     DOI: 10.5858/2003-127-978-AQRRAM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Validation of human papillomavirus genotyping by signature DNA sequence analysis.

Authors:  Sin Hang Lee; Veronica S Vigliotti; Jessica S Vigliotti; Suri Pappu
Journal:  BMC Clin Pathol       Date:  2009-05-22

2.  Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens.

Authors:  Sin Hang Lee; Veronica S Vigliotti; Suri Pappu
Journal:  J Clin Pathol       Date:  2009-10-26       Impact factor: 3.411

3.  Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.

Authors:  Abida Siddiqa; Maidah Zainab; Ishtiaq Qadri; Muhammad Faraz Bhatti; Joanna L Parish
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.